Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region

Background & Objectives: Biological disease-modifying antirheumatic drugs (bDMARDs) for the treatment of rheumatoid arthritis (RA) are not always accessible to all patients in accordance with international guidelines, partly owing to their high direct costs against a background of restricted hea...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaló, Zoltán, Vokó, Zoltán, Östör, Andrew, Clifton-Brown, Emma, Vasilescu, Radu, Battersby, Alysia, Gibson, Edward
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Routledge 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508389/
https://www.ncbi.nlm.nih.gov/pubmed/28740623
http://dx.doi.org/10.1080/20016689.2017.1345580

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508389/
https://www.ncbi.nlm.nih.gov/pubmed/28740623
http://dx.doi.org/10.1080/20016689.2017.1345580

Ejemplares similares